Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma.

J Clin Oncol

Department of Internal Medicine, Division of Hematology and Oncology, Michigan State University, East Lansing, MI, USA.

Published: May 2008

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.14.7603DOI Listing

Publication Analysis

Top Keywords

cetuximab-related tumor
4
tumor lysis
4
lysis syndrome
4
syndrome metastatic
4
metastatic colon
4
colon carcinoma
4
cetuximab-related
1
lysis
1
syndrome
1
metastatic
1

Similar Publications

Background: ENCORE, an observational, prospective, open-label study, investigated real-world treatment practices and outcomes with cetuximab plus platinum-based therapy (PBT) in first-line (1L) recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

Aims: This multinational study aimed to investigate the long-term use of cetuximab plus PBT for 1L R/M SCCHN in a clinical setting. In particular, this study aimed to explore clinical considerations such as the decision to prescribe cetuximab plus PBT in R/M SCCHN, the mode and duration of treatment, and patient outcomes.

View Article and Find Full Text PDF

Background: The antiepidermal growth factor receptor (EGFR) monoclonal antibody cetuximab and immune checkpoint inhibitors (ICIs) are the current front-line treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, understanding of the efficacy of cetuximab-containing regimens in patients who fail ICI treatments is limited. In this study, we present the efficacy of cetuximab-based regimens in heavily pretreated R/M HNSCC patients after progression to ICIs.

View Article and Find Full Text PDF

Cetuximab is the first-line treatment for advanced metastatic colon cancer. But cetuximab can cause electrolyte disturbances, including hypomagnesemia and hypokalemia. Among them, hypokalemia is often caused by hypomagnesemia, not directly caused by cetuximab.

View Article and Find Full Text PDF

Background: Cutaneous squamous cell carcinoma of the head/neck (CSCCHN) is common due to chronic sun exposure. As CSCCHN highly expresses EGFR, we prospectively studied postoperative concurrent cetuximab with radiotherapy for locally advanced CSCCHN (LA-CSCCHN).

Materials And Methods: Single-institutional phase II trial of LA-CSCCHN (NCT XXXX).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!